Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review)

  • Authors:
    • Jorge Organista-Nava
    • Yazmín Gómez-Gómez
    • Berenice Illades-Aguiar
    • Marco Antonio Leyva-Vázquez
  • View Affiliations

  • Published online on: July 19, 2016     https://doi.org/10.3892/or.2016.4948
  • Pages: 1226-1232
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs) are a class of small endogenous non-coding RNAs that play important regulatory roles by targeting mRNAs for cleavage or translational repression. miRNAs act in diverse biological processes including development, cell growth, apoptosis, and hematopoiesis. The miRNA expression is associated with specific cytogenetic changes and can also be used to discriminate between the different subtypes of leukemia in acute lymphoblastic leukemia with common translocations, it is shown that the miRNAs have the potential to be used for clinical diagnosis and prognosis. We reviewed the roles of miRNA here with emphasis on their function in human leukemia and the mechanisms of the TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins on miRNAs expression in acute lymphoblastic leukemia.

1. Introduction

Leukemia is a malignancy of the hematopoietic system characterized by diffuse replacement of the bone marrow by neoplastic cells (1). Acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) are oncohematologic diseases in which the process of differentiation and limited proliferation that characterizes normal hematopoiesis is altered and replaced by a malignant clonal expansion of immature hematopoietic cells (blasts) in the bone marrow or peripheral blood (25).

Epidemiological studies indicate that the annual incidence rates of childhood ALL vary worldwide between one and four new cases per 100,000 children younger than 15 years, with a peak incidence at approximately 2–5 years of age (68), whereas AML has been observed with an incidence of 3.7 per 100,000 persons and an age-dependent mortality of 2.7 to nearly 18 per 100,000 persons (9).

Abnormalities in chromosome number as well as structural rearrangements (translocations) are detected in 60–80% of patients with ALL, whereas the remaining 20–40% have a normal karyotype (914). In addition to those with a normal karyotype, t(12;21)(p13;q22);TEL/AML1 (ETV6-RUNX1), t(9;22)(q34,q11); BCR/ABL (BCR-ABL1), t(4;11) (q21;q23); MLL/AF4 (KMT2A/AFF1), t(1;19)(q23;p13); E2A/PBX1 (TCF3-PBX1), are among the most common cytogenetic subtypes in ALL (1012,14), and have been incorporated in the World Health Organization (WHO) classification as the criteria for subclassification of acute leukemia (15).

ALL can be distinguished from AML using morphologic, immunohistochemical, and immunologic methods (16). The study by Golub et al showed that the gene expression profiles can discriminate the ALL from AML (17). However, the precise genes and pathways that exert critical control over determination of lineage fate during leukemia development remain unclear (18).

Hematopoiesis is a highly regulated process of the differentiation, proliferation hematopoietic stem cells give rise to all the blood lineages: the myeloid lineage, which comprises neutrophils, eosinophils, basophils, monocytes, macrophages, megakaryocytes, platelets and erythrocytes; and the lymphoid lineage, which includes T and B cells (19,20).

The process is modulated by a series of molecular events, and there is increasing evidence that miRNAs have important roles in modulating hematopoietic process by targeting the expression of transcription factors and genes that are involved in the regulation of cell proliferation, metabolism, and apoptosis (21). Aberrant expression of many different miRNAs has been observed in several cancers, including hematological malignancies. Furthermore, approximately 50% of miRNAs are located at fragile sites and genomic regions in the human genome associated with cancer (22). In this review, we summarized the association of the miRNA expression with chromosomal translocations in acute leukemia, with a specific focus on acute lymphoblastic leukemia.

2. miRNA expression and oncoproteins in acute lymphoblastic leukemia

TEL/AML1; t(12;21)(p13;q22)

TEL/AML1 t(12;21) (p13;q22) fusion gene, resulting from 12;21 chromosomal translocation, is believed to be the most common molecular genetic abnormality in childhood acute lymphoblastic leukemia (23). The resulting fusion protein has the AML1 DNA binding domain and the TEL protein interaction domain and has been shown to maintain transcription factor properties and bind DNA (24,25). TEL/AML1 act as a transcription factor that reduce the expression of tumor suppressor and increase antiapoptotic genes (26) and also alters the regulation of miRNA expression (27,28) (Table I). For example, the miR-320a and miR-498 tumor suppressor are significantly lower in TEL/AML1-positive acute lymphoblastic leukemias (28). Interestingly, these miRNAs can inhibit the expression of survivin in leukemia cells, inducing apoptosis, suggests that miR-320a and miR-498 are potential tumor suppressors or miRNAs that may play a critical role in the leukemic process (28). The TEL/AML1 protein is generally a transcriptional repressor due to its known ability to recruit chromatin repressors such as histone deacetylases, nuclear receptor corepressors (Fig. 1).

Table I

Expression of miRNAs in rearrangement-positive ALL.

Table I

Expression of miRNAs in rearrangement-positive ALL.

miRNAsFunction in canceraExpressionAuthors/(Ref.)
TEL/AML1-positive rearrangement
 miR-26bOG/TSGDownregulationDiakos et al (28)
 miR-320aTSG
 miR-494TSG
 miR-213TSGDownregulation
 miR-221OG/TSG
 miR-99aOGUpregulationSchotte et al (27)
 miR-100OG/TSG
 miR-125bOG
 miR-126OG/TSG
 miR-383OG/TSG
 miR-629OG
 miR-125bOGUpregulationGefen et al (29)
BCR/ABL-positive rearrangement
 miR-17OGUpregulationScherr et al (33)
 miR-18OG
 miR-19aOG
 miR-20aOG
 miR-93OGDownregulationSchotte et al (27)
 miR-103OG/TSG
 miR-148bTSG
 miR-210OG/TSG
 miR-301TSG
 miR-331TSG
 miR-345OG/TSG
 miR-484TSG
 miR-1226TSG
MLL/AF4-positive rearrangement
 Let-7bTSGDownregulationMi et al (18)
 miR-128aOG/TSGUpregulation
 miR-128bOG/TSG
 miR-128aOG/TSGUpregulationOliveira et al (47)
 miR-128bOG/TSG
 miR-181bOG
 miR-143TSGDownregulationDou et al (46)
 mir-196bOGUpregulationPopovic et al (50) and Li et al (51)
TCF3/PBX1-positive rearrangement
 miR-24OG/TSGDownregulationSchotte et al (27)
 miR-126OG/TSG
 miR-146aTSG
 miR-193aTSG
 miR-365TSG
 miR-511TSG
 miR-545TSG
 miR-181OGUpregulationSchotte et al (56)
 miR-708OG
 mir-196bTSGDownregulation

{ label (or @symbol) needed for fn[@id='tfn1-or-36-03-1226'] } OG, oncogene; TSG, tumor suppressor gene.

a The miRBase website (http://www.mirbase.org/) was used to assign the functions of miRNAs.

Other upregulation miRNAs in TEL/AML1-positive acute lymphoblastic leukemias have also been reported (2729) and it has been observed that AML1 can associate with coactivators to regulate the promoters of its target genes (30). For example, miR-125b is an oncogenic miRNA by its anti-apoptotic activity which is associated with a marked inhibition of caspase 3 activation and the cleavage of its substrate PARP (29), suggesting an active role for miR-125b in the leukemogenesis (31) and its expression is an independent event from TEL/AML1 protein (Fig. 1).

BCR/ABL1; t(9;22)(q34,q11)

BCR/ABL1 or Philadelphia (Ph) chromosome is a product of the t(9;22), which fuses the Abelson kinase gene (ABL1) from chromosome 9 with the breakpoint cluster region (BCR) from chromosome 22 that expresses the BCR-ABL1 fusion protein: a constitutively active tyrosine kinase. The BCR/ABL1 fusion protein is a hallmark present in a fraction of B progenitor ALL cases that have a particularly poor prognosis (32).

Several miRNAs are overexpressed in BCR/ABL1-positive ALL (27,33) (Table I). BCR/ABL has been shown to upregulate Pim-1 (34,35), E2F3 (36) and c-Myc (35) who regulate the transcriptional expression of miR-17-92 clusters. Recently, it was reported that BIM, a proapoptotic member, is a direct target of miR-17-92 clusters (37). It was demonstrated that BIM is poorly expressed in ALL (38), while the members of the miR-17-92 clusters that have been reported to be upregulated in BCR/ABL1-positive ALL (33). These data demonstrate that the upregulation of miR-17-92 cluster expression observed in BCR/ABL1-positive ALL could have an important role in survival of cells in leukemia (Fig. 2).

Interestingly, a direct relationship between BCR/ABL activity and cyclin D2 expression in BCR/ABL-positive cells has been demonstrated (39,40); these reports suggest the importance of cyclin D2 in mediating the proliferative signals from BCR/ABL and show that BCR/ABL regulates cyclin D2 expression at the transcriptional level. A recent study showed that miR-93 is downregulated in BCR/ABL-positive patients (27). Interestingly, this miRNA can inhibit the expression of cyclin D2 which leads to cell cycle progression (41). Overexpression of cyclins D2 in BCR/ABL-positive hematopoietic cell have been reported (39,40). The abnormal expression of cyclin D2 may influence the initiation of tumorigenesis, including leukemogenesis (42), suggesting that downregulation of miR-93 could be involved to the leukemogenesis at least partly via upregulation of cyclin D2 expression in BCR/ABL-positive cells (Fig. 2).

MLL/AF4; t(4;11)(q21;q23)

The t(4;11)(q21;q23) involving the genes MLL and AF4 (alias for AFF1) is detected in 50-70% of infant leukemia. MLL/AF4, an MLL fusion protein that is associated with infant pro-B acute lymphoblastic leukemias (43), and it is usually associated with a poor prognosis (44). Rearrangements of the MLL gene result in a fusion protein that retain the DNA binding capacities, the CXXC domain, which binds to non-methylated CpG DNA sites, as well as their DNA methyltransferase activity (transcriptional activation/repression domain of MLL), it is possible that the MLL-fusion proteins directly regulate a subset of genes (45).

Recent studies indicate that MLL/AF4 regulates the expression of miRNas (Table I), which can play a role in leukemogenesis by stimulating proliferation and inducing a block in differentiation of hematopoietic cells (46,47). Dou et al demonstrated that the expression levels of miR-143 are significantly lower in MLL-AF4-positive cells (46). PI3K/AKT/mTOR is a survival pathway and plays an important role in cell proliferation, differentiation and apoptosis. Its abnormal activation has been found in cases of MLL/AF4-positive ALL (48). miR-143 has been shown to decrease the level of Akt at translational level (49). miR-143 is epigenetically repressed by promoter hypermethylation in MLL/AF4-positive primary blasts and cell lines, which was directly associated with expression of the MLL/AF4 oncogene (46). Additionally, it was shown that MLL/AF4 is a target for miR-143, and that DNA methylation decreases the expression of miR-143 in MLL/AF4-positive ALL (46), it is possible that the MLL/AF4 proteins directly downregulate the miR143 expression by the DNA methyltransferase activity of MLL (Fig. 3).

miR-196b is an oncogene and appears to be required for MLL/AF4-mediated cell transformation and it was reported that miR-196b is upregulated in MLL/AF4-positive cell lines (50). MLL/AF4 protein regulate the transcriptional expression of miR-196b by increasing levels of K79me2 on the promoter of miR-196b (50,51). FAS plays a central role in the physiological regulation of apoptosis (52), and it has been implicated in the leukemogenesis (51). FAS is direct target of miR-196b and is negatively regulated at the mRNA and protein levels (51). It was demonstrated that FAS is poorly expressed in MLL/AF4-positive human leukemic cells, compared to the normal cells (Table I) (50,51). Li et al found that the low expression of FAS leads to inhibition of FAS-mediated apoptosis (51). These data demonstrate that the upregulation of miR-196b expression observed in MLL/AF4-positive cell has an important role in cell survival in leukemia by targeting FAS mRNA in MLL/AF4-positive cells (Fig. 3).

TCF3/PBX1; t(1;19)(q23;p13)

The t(1;19)(q23;p13) is one of the most frequent translocations in B-acute lymphoblastic leukemia (B-ALL), and is observed in both adult and pediatric populations at an overall frequency of 6% (53). This translocation is the result from the fusion of TCF3 (transcription factor 3) found at 19p13 and PBX1 (pre-B cell leukemia homebox 1) found at 1q23 forming a chimeric gene whose protein product alters cell differentiation arrest, among other cellular processes (54). TCF3/PBX1 encodes a transcription factor bearing the transactivation domain of TCF3 and the DNA-binding domain of PBX1, which facilitates the activation or repression of genes (55).

Several miRNAs are downregulated or upregulated in TCF3/PBX1-positive ALL (27,56) (Table I). For example, miR-126 plays a pivotal role in restraining cell cycle progression of hematopoietic stem cell in vitro and in vivo, it was observed that the downregulation of this miRNA resulted in cell cycle progression and hematopoietic stem cell expansion (57). miR-126 is significantly lower expressed in TCF3/PBX1-ALL and was shown to correlate with in vitro resistance to vincristine and daunorubicin in childhood ALL (27). This suggests that miR-126 may have potential in prognosis prediction and therapeutic application in ALL patients.

3. miRNAs in diagnosis and prognosis of ALL

MicroRNAs are associated with the regulation of normal hematopoiesis and their disruption has been related to many types of cancer, including hematological malignancies. Pediatric ALL samples showed lower expression levels of miR-100, miR-196b and let-7e, while miR-128a and miR-181b were overexpressed compared to normal pediatric samples (47). miR-451 and miR-373 were downregulated, while an increase in miR-222, mIR-339 and miR-142-3p was identified in pre-B-ALL cells compared to control CD19+ (58). It is also possible to identify between different ALL subtypes (B-ALL and T-ALL) using miRNA signatures: miR-151 (downregulated in T-ALL), miR-148a and miR-424 (both highly expressed in T-ALL) could all be used to discriminate between these two leukemic subtypes (59,60). Furthermore, it is possible to distinguish between B-ALL subtypes using miRNA expression, as exemplified by miR-629 having high expression in MLL-AF4, miR-425-5p miR-191 and miR-128 being highly expressed in E2A-PBX1. BCR-Abl also generates higher expression of miR-146b and miR-126 (59).

Prognosis can be tested by miRNA expression. miR-708 was upregulated in relapse, whereas both miR-223 and miR-27a were highly expressed in patients during remission, suggesting that these dysregulated miRNAs play important roles in controlling disease (61). It also was reported that vincristine-resistant ALL patients expressed higher levels of miR-125b (27). The miR-10a, miR-134 and miR-214 expression was linked to a favorable outcome in pediatric ALL, while the expression of miR-33 was associated with an unfavorable prognosis in T-ALL compared to in normal thymocytes (27).

4. Conclusions

The discovery of miRNAs and their association with TEL/AML1, BCR/ABL, MLL/AF4, E2A/PBX1 oncoproteins in acute lymphoblastic leukemia have provided valuable information on potential diagnostic and/or prognostic biomarkers, as well as monitoring the disease progression. Moreover, a potential role of the microRNAs has been suggested in specific subtypes of acute lymphoblastic leukemia and in the development of different phenotypes. Also it is noted that the changes of miRNA expression levels may play an important role in the genesis and evolution of acute lymphoblastic leukemia. Thus, the mechanism of miRNA regulation by TEL/AML1, BCR/ABL, MLL/AF4, E2A/PBX1 oncoproteins is very complex. Studies are needed to clearly demonstrate the effect of miRNAs in leukemogenesis and its practical implications.

Acknowledgments

J.O.N and Y.G.G. were recipients of fellowships from the Programa de Apoyo a los Estudios de Posgrado, Universidad Nacional Autónoma de Mexico (PAEP-UNAM).

References

1 

Cartwright RA, Alexander FE, McKinney PA and Ricketts TJ: Leukaemia and lymphoma. An atlas of distribution within areas of England and Wales 1984–1988. Stat Med. 11:135–136. 1992.

2 

Graubert TA and Mardis ER: Genomics of acute myeloid leukemia. Cancer J. 17:487–491. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Greaves M: Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 6:193–203. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Greaves MF: Aetiology of acute leukaemia. Lancet. 349:344–349. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Miller DR and Miller LP: Acute lymphoblastic leukemia in children: An update of clinical, biological, and therapeutic aspects. Crit Rev Oncol Hematol. 10:131–164. 1990. View Article : Google Scholar : PubMed/NCBI

6 

Redaelli A, Laskin BL, Stephens JM, Botteman MF and Pashos CL: A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl). 14:53–62. 2005. View Article : Google Scholar

7 

Linabery AM and Ross JA: Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer. 112:416–432. 2008. View Article : Google Scholar

8 

Howard SC, Metzger ML, Wilimas JA, Quintana Y, Pui CH, Robison LL and Ribeiro RC: Childhood cancer epidemiology in low-income countries. Cancer. 112:461–472. 2008. View Article : Google Scholar

9 

Deschler B and Lübbert M: Acute myeloid leukemia: Epidemiology and etiology. Cancer. 107:2099–2107. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Look AT: Oncogenic transcription factors in the human acute leukemias. Science. 278:1059–1064. 1997. View Article : Google Scholar : PubMed/NCBI

11 

Pui C-H and Jeha S: New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 6:149–165. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Rowley JD: Chromosome translocations: Dangerous liaisons revisited. Nat Rev Cancer. 1:245–250. 2001. View Article : Google Scholar

13 

Haferlach T, Bacher U, Kern W, Schnittger S and Haferlach C: Diagnostic pathways in acute leukemias: A proposal for a multimodal approach. Ann Hematol. 86:311–327. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Armstrong SA and Look AT: Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 23:6306–6315. 2005. View Article : Google Scholar : PubMed/NCBI

15 

Steven HS, Swerdlow EC, Harris NL, et al: International WHO classification of tumours of haematopoietic and lymphoid tissues. Agency for Research on Cancer; Lyon: pp. 274–288. 2008

16 

Löwenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999. View Article : Google Scholar : PubMed/NCBI

17 

Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 286:531–537. 1999. View Article : Google Scholar : PubMed/NCBI

18 

Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, et al: MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA. 104:19971–19976. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Iwasaki H and Akashi K: Hematopoietic developmental pathways: On cellular basis. Oncogene. 26:6687–6696. 2007. View Article : Google Scholar : PubMed/NCBI

20 

Doulatov S, Notta F, Laurenti E and Dick JE: Hematopoiesis: A human perspective. Cell Stem Cell. 10:120–136. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Sun K and Lai EC: Adult-specific functions of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Jamil A, Theil KS, Kahwash S, Ruymann FB and Klopfenstein KJ: TEL/AML-1 fusion gene. its frequency and prognostic significance in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 122:73–78. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Golub TR, McLean T, Stegmaier K, Carroll M, Tomasson M and Gilliland DG: The TEL gene and human leukemia. Biochim Biophys Acta. 1288:M7–M10. 1996.PubMed/NCBI

25 

Lorsbach RB and Downing JR: The role of the AML1 transcription factor in leukemogenesis. Int J Hematol. 74:258–265. 2001. View Article : Google Scholar : PubMed/NCBI

26 

Krug U, Ganser A and Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 21:3475–3495. 2002. View Article : Google Scholar : PubMed/NCBI

27 

Schotte D, De Menezes RX, Akbari Moqadam F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R and Den Boer ML: MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 96:703–711. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Diakos C, Zhong S, Xiao Y, Zhou M, Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M, Wiencke JK, et al: TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood. 116:4885–4893. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A, Edry L, Hertzberg L, Shomron N, Williams O, et al: Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia. 24:89–96. 2010. View Article : Google Scholar :

30 

Zelent A, Greaves M and Enver T: Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene. 23:4275–4283. 2004. View Article : Google Scholar : PubMed/NCBI

31 

Bousquet M, Harris MH, Zhou B and Lodish HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA. 107:21558–21563. 2010. View Article : Google Scholar : PubMed/NCBI

32 

Faber J, Gregory RI and Armstrong SA: Linking miRNA regulation to BCR-ABL expression: The next dimension. Cancer Cell. 13:467–469. 2008. View Article : Google Scholar : PubMed/NCBI

33 

Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor J, et al: Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia. 28:554–565. 2014. View Article : Google Scholar

34 

Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA and Skorski T: Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 99:4531–4539. 2002. View Article : Google Scholar : PubMed/NCBI

35 

Thomas M, Lange-Grünweller K, Hartmann D, Golde L, Schlereth J, Streng D, Aigner A, Grünweller A and Hartmann RK: Analysis of transcriptional regulation of the human miR-17-92 cluster; evidence for involvement of Pim-1. Int J Mol Sci. 14:12273–12296. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, et al: Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: Requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111:816–828. 2008. View Article : Google Scholar

37 

Mogilyansky E and Rigoutsos I: The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 20:1603–1614. 2013. View Article : Google Scholar : PubMed/NCBI

38 

Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, Chew FT and Yeoh AE: BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol. 39:321–329. 329.e1–329.e3. 2011. View Article : Google Scholar

39 

Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, Peters G, Mahon FX, Köhler T, Goldman JM and Melo JV: Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 61:8005–8013. 2001.PubMed/NCBI

40 

Parada Y, Banerji L, Glassford J, Lea NC, Collado M, Rivas C, Lewis JL, Gordon MY, Thomas NS and Lam EW: BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 276:23572–23580. 2001. View Article : Google Scholar : PubMed/NCBI

41 

Yu X-F, Zou J, Bao Z-J and Dong J: miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol. 17:4711–4717. 2011. View Article : Google Scholar : PubMed/NCBI

42 

Ohtsubo M and Roberts JM: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science. 259:1908–1912. 1993. View Article : Google Scholar : PubMed/NCBI

43 

Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S and Secker-Walker LM: Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia. 12:779–787. 1998. View Article : Google Scholar : PubMed/NCBI

44 

Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH and Pui CH: Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood. 87:2870–2877. 1996.PubMed/NCBI

45 

Tamai H and Inokuchi K: 11q23/MLL acute leukemia: Update of clinical aspects. J Clin Exp Hematop. 50:91–98. 2010. View Article : Google Scholar

46 

Dou L, Zheng D, Li J, Li Y, Gao L, Wang L and Yu L: Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. Oncogene. 31:507–517. 2012. View Article : Google Scholar

47 

de Oliveira JC, Scrideli CA, Brassesco MS, Morales AG, Pezuk JA, Queiroz RP, Yunes JA, Brandalise SR and Tone LG: Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res. 36:293–298. 2012. View Article : Google Scholar

48 

Urtishak KA, Li-San W, Teachey DT, Sarah TK, Barrett JS, Chen I-ML, Atlas SR, Harvey RC, Heerema NA, Carroll AJ, et al: PI3K/AKT/mTOR signaling is a significant druggable pathway in infant acute lymphoblastic leukemia. Blood. 122:16692013.

49 

Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y, Naoe T and Akao Y: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI

50 

Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, et al: Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 113:3314–3322. 2009. View Article : Google Scholar : PubMed/NCBI

51 

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, et al: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun. 3:6882012. View Article : Google Scholar : PubMed/NCBI

52 

Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y and Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:233–243. 1991. View Article : Google Scholar : PubMed/NCBI

53 

Tirado CA, Shabsovich D, Yeh L, Pullarkat ST, Yang L, Kallen M and Rao N: A (1;19) translocation involving TCF3-PBX1 fusion within the context of a hyperdiploid karyotype in adult B-ALL: A case report and review of the literature. Biomark Res. 3:42015. View Article : Google Scholar : PubMed/NCBI

54 

Heim S and Mitelman F: Cancer Cytogenetics. 3. Wiley; Online Library, Hoboken, NJ: 2009

55 

Hajingabo LJ, Daakour S, Martin M, Grausenburger R, Panzer-Grümayer R, Dequiedt F, Simonis N and Twizere JC: Predicting interactome network perturbations in human cancer: Application to gene fusions in acute lymphoblastic leukemia. Mol Biol Cell. 25:3973–3985. 2014. View Article : Google Scholar : PubMed/NCBI

56 

Schotte D, Chau JCK, Sylvester G, Liu G, Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R and den Boer ML: Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia. 23:313–322. 2009. View Article : Google Scholar

57 

Lechman ER, Gentner B, van Galen P, Giustacchini A, Saini M, Boccalatte FE, Hiramatsu H, Restuccia U, Bachi A, Voisin V, et al: Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell. 11:799–811. 2012. View Article : Google Scholar : PubMed/NCBI

58 

Ju X, Li D, Shi Q, Hou H, Sun N and Shen B: Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. Pediatr Hematol Oncol. 26:1–10. 2009. View Article : Google Scholar : PubMed/NCBI

59 

Fulci V, Colombo T, Chiaretti S, Messina M, Citarella F, Tavolaro S, Guarini A, Foà R and Macino G: Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer. 48:1069–1082. 2009. View Article : Google Scholar : PubMed/NCBI

60 

Saki N, Abroun S, Soleimani M, Hajizamani S, Shahjahani M, Kast RE and Mortazavi Y: Involvement of microRNA in T-cell differentiation and malignancy. Int J Hematol Oncol Stem Cell Res. 9:33–49. 2015.PubMed/NCBI

61 

Han B-W, Feng D-D, Li Z-G, Luo XQ, Zhang H, Li XJ, Zhang XJ, Zheng LL, Zeng CW, Lin KY, et al: A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet. 20:4903–4915. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September-2016
Volume 36 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Organista-Nava J, Gómez-Gómez Y, Illades-Aguiar B and Leyva-Vázquez MA: Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review). Oncol Rep 36: 1226-1232, 2016.
APA
Organista-Nava, J., Gómez-Gómez, Y., Illades-Aguiar, B., & Leyva-Vázquez, M.A. (2016). Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review). Oncology Reports, 36, 1226-1232. https://doi.org/10.3892/or.2016.4948
MLA
Organista-Nava, J., Gómez-Gómez, Y., Illades-Aguiar, B., Leyva-Vázquez, M. A."Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review)". Oncology Reports 36.3 (2016): 1226-1232.
Chicago
Organista-Nava, J., Gómez-Gómez, Y., Illades-Aguiar, B., Leyva-Vázquez, M. A."Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review)". Oncology Reports 36, no. 3 (2016): 1226-1232. https://doi.org/10.3892/or.2016.4948